Investigational reverse transcriptase inhibitors for the treatment of HIV

Theodore Cory, Narasimha M. Midde, P. S.S. Rao, Santosh Kumar

Research output: Contribution to journalReview article

7 Citations (Scopus)

Abstract

Introduction: While considerable advances have been made in the development of antiretroviral agents, there is still work to be done. Reverse transcriptase inhibitors are important drugs for the treatment of HIV, and considerable research is currently ongoing to develop new agents and to modify currently existing agents.Areas covered: Herein, the authors discuss both investigational nucleoside reverse transcriptase inhibitors (NRTIs) and non-nucleoside reverse transcriptase inhibitors (NNRTIs), including agents that are in various stages of development. They also discuss novel formulations that are being investigated for currently available drugs, and discuss the advantages that these new formulations may provide.Expert opinion: New formulations and co-formulations of currently existing antiretrovirals will represent an important area of development, as a means to improve adherence for HIV-positive individuals. New formulations will continue to be developed, with a focus on allowing for less-frequent administration, as well increasing drug concentrations at local sites such as vaginal tissue, rectal tissue and sites in the immune system.

Original languageEnglish (US)
Pages (from-to)1219-1228
Number of pages10
JournalExpert Opinion on Investigational Drugs
Volume24
Issue number9
DOIs
StatePublished - Sep 2 2015

Fingerprint

Reverse Transcriptase Inhibitors
HIV
Pharmaceutical Preparations
Anti-Retroviral Agents
Expert Testimony
Nucleosides
Immune System
Research

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)

Cite this

Investigational reverse transcriptase inhibitors for the treatment of HIV. / Cory, Theodore; Midde, Narasimha M.; Rao, P. S.S.; Kumar, Santosh.

In: Expert Opinion on Investigational Drugs, Vol. 24, No. 9, 02.09.2015, p. 1219-1228.

Research output: Contribution to journalReview article

@article{f40b6d4012ef432090a2b148b117e27d,
title = "Investigational reverse transcriptase inhibitors for the treatment of HIV",
abstract = "Introduction: While considerable advances have been made in the development of antiretroviral agents, there is still work to be done. Reverse transcriptase inhibitors are important drugs for the treatment of HIV, and considerable research is currently ongoing to develop new agents and to modify currently existing agents.Areas covered: Herein, the authors discuss both investigational nucleoside reverse transcriptase inhibitors (NRTIs) and non-nucleoside reverse transcriptase inhibitors (NNRTIs), including agents that are in various stages of development. They also discuss novel formulations that are being investigated for currently available drugs, and discuss the advantages that these new formulations may provide.Expert opinion: New formulations and co-formulations of currently existing antiretrovirals will represent an important area of development, as a means to improve adherence for HIV-positive individuals. New formulations will continue to be developed, with a focus on allowing for less-frequent administration, as well increasing drug concentrations at local sites such as vaginal tissue, rectal tissue and sites in the immune system.",
author = "Theodore Cory and Midde, {Narasimha M.} and Rao, {P. S.S.} and Santosh Kumar",
year = "2015",
month = "9",
day = "2",
doi = "10.1517/13543784.2015.1058357",
language = "English (US)",
volume = "24",
pages = "1219--1228",
journal = "Expert Opinion on Investigational Drugs",
issn = "1354-3784",
publisher = "Taylor and Francis Ltd.",
number = "9",

}

TY - JOUR

T1 - Investigational reverse transcriptase inhibitors for the treatment of HIV

AU - Cory, Theodore

AU - Midde, Narasimha M.

AU - Rao, P. S.S.

AU - Kumar, Santosh

PY - 2015/9/2

Y1 - 2015/9/2

N2 - Introduction: While considerable advances have been made in the development of antiretroviral agents, there is still work to be done. Reverse transcriptase inhibitors are important drugs for the treatment of HIV, and considerable research is currently ongoing to develop new agents and to modify currently existing agents.Areas covered: Herein, the authors discuss both investigational nucleoside reverse transcriptase inhibitors (NRTIs) and non-nucleoside reverse transcriptase inhibitors (NNRTIs), including agents that are in various stages of development. They also discuss novel formulations that are being investigated for currently available drugs, and discuss the advantages that these new formulations may provide.Expert opinion: New formulations and co-formulations of currently existing antiretrovirals will represent an important area of development, as a means to improve adherence for HIV-positive individuals. New formulations will continue to be developed, with a focus on allowing for less-frequent administration, as well increasing drug concentrations at local sites such as vaginal tissue, rectal tissue and sites in the immune system.

AB - Introduction: While considerable advances have been made in the development of antiretroviral agents, there is still work to be done. Reverse transcriptase inhibitors are important drugs for the treatment of HIV, and considerable research is currently ongoing to develop new agents and to modify currently existing agents.Areas covered: Herein, the authors discuss both investigational nucleoside reverse transcriptase inhibitors (NRTIs) and non-nucleoside reverse transcriptase inhibitors (NNRTIs), including agents that are in various stages of development. They also discuss novel formulations that are being investigated for currently available drugs, and discuss the advantages that these new formulations may provide.Expert opinion: New formulations and co-formulations of currently existing antiretrovirals will represent an important area of development, as a means to improve adherence for HIV-positive individuals. New formulations will continue to be developed, with a focus on allowing for less-frequent administration, as well increasing drug concentrations at local sites such as vaginal tissue, rectal tissue and sites in the immune system.

UR - http://www.scopus.com/inward/record.url?scp=84939811730&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84939811730&partnerID=8YFLogxK

U2 - 10.1517/13543784.2015.1058357

DO - 10.1517/13543784.2015.1058357

M3 - Review article

VL - 24

SP - 1219

EP - 1228

JO - Expert Opinion on Investigational Drugs

JF - Expert Opinion on Investigational Drugs

SN - 1354-3784

IS - 9

ER -